Skip to content

Study of the utility of BPO products for acne vulgaris on trunk (back and chest)

Study of the utility of BPO products for acne vulgaris on trunk (back and chest) - Study of the utility of BPO products for acne vulgaris on trunk

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000021795
Enrollment
40
Registered
2016-04-10
Start date
2016-05-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne vulgaris

Interventions

BPO gel will be applied for 12 weeks. Topical antimicrobial agent(Nadifloxacin or Clindamycin) will be applied for 12 weeks.

Sponsors

Non-Profit Organization Health Institute Research of Skin
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Patients with acne vulgaris who have 10 or more inflammatory rashes on the trunk(Chest or bBack) 2) Patients who provided written informed consent after receiving an explanation of the details of the study 3) Patients aged 16 years old or older at the time informed consent was provided For patients younger than 20 years old, representatives (parents, etc.) are required to provide informed consent.

Exclusion criteria

Exclusion criteria: 1) Patients who had received treatment for acne vulgaris within one month of the start of the study 2) Patients in whom the study drug is contraindicated 3) Patients with continuous use of non-steroidal anti-inflammatory drugs (ibuprofen, etc.) 4) Pregnant women, those who may be pregnant, lactating women, and women who hope to become pregnant during the study period 5) Patients who were considered inappropriate for the study by an investigator 6) Patients who had participated in other clinical studies and phase IV clinical trials of drugs for acne vulgaris within 6 months of the start of the study

Design outcomes

Primary

MeasureTime frame
Decrease in the number of inflammatory rashes / during 12 weeks of observation period

Countries

Japan

Contacts

Public ContactNaomi Kanazawa

EBC&M LLC. Project planning & Development department

naomi_kanazawa@ebc-m.com03-6435-3833

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026